COMPARISON OF D-DIMER LEVEL AND PLATELET COUNT IN INDIVIDUALS WITH AND WITHOUT SICKLE CELL ANAEMIA

Abstract

Aim: This study aimed to assess the D-dimer levels and platelet count in sickle cell anaemia patients and compare with those of the control subjects.

Materials and Methods: This study is a cross–sectional comparative study which enrolled 58 sickle cell anaemia patients (25 males and 33 females) in a stable state at the Obafemi Awolowo University Teaching Hospital in Ile-Ife, Osun State, Nigeria, as well as 25 healthy controls (11 males and 24 females). Venous blood (4.5 mL) was collected from both the patient and control into a vial containing 0.5 ml of 3.2% trisodium citrate. D-dimer levels was analysed using ELISA method. Platelet counts were determined (from 5ml venous sample collected with EDTA) using haematology autoanalyzer.

Results: There was a significant rise in D-dimer levels in sickle cell patients, with mean values of 1771.86 ng/mL and 1986.00 ng/mL for males and females, respectively, in the steady state compared to the D-dimer levels of controls, with mean values of 199.24 and 322.21 ng/mL for males and females, respectively. Platelet count was significantly higher in SCA patients than in the control subjects. There is perfect correlation between D-dimer and platelet counts in both patients and control (r=1, n=57, P=0.000) and (r=1, n=30, P=0.000)

Conclusion: This study showed the hypercoagulable state and thrombotic risk associated with SCA. The strong correlation between D-dimer levels and platelet counts suggests a potential interplay between platelet activation and coagulation activation in SCA, warranting further investigation into therapeutic interventions targeting these pathways.

Zenodo DOI: https://doi.org/10.5281/zenodo.14543328

Keywords:

D-dimer, platelet count, Sickle cell anaemia, steady state

References

Hebbel, R. P., & Key, N. S. (2016). Microparticles in sickle cell anaemia: Promise and pitfalls. British Journal of Haematology, 174(1), 16-29.

Kato, G. J., Hebbel, R. P., Steinberg, M. H., Gladwin, M. T. (2017). Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions. American Journal of Hematology, 91(2), 927-942.

Martínez, C., Wallenhorst, C., Siu, A., & Tsaras, G. (2020). Elevated D-dimer is associated with acute ischemic stroke in children with sickle cell anaemia. Pediatric Blood & Cancer, 67(7), e28319.

Tsaras, G., Owusu-Ansah, A., Boateng, F. O., & Amoateng-Adjepong, Y. (2009). Complications associated with sickle cell anaemia: a brief narrative review. The American Journal of Medicine, 122(11), 1021-1026.

Wood, K. C., Granger, D. N., & Sickle, C. (2014). Sickle cell disease: role of reactive oxygen and nitrogen metabolites. Clinical and Experimental Pharmacology and Physiology, 41(7), 458-465.

Ataga KI and Orringer EP. Hypercoagulability in sickle cell disease: a curious paradox. Am J Med, 2019;115(9), 721–728.

Uche CL, Abali IO, Ezirim EO, Airaodion AI. Sickle Cell Anemia Contributes to Liver Abnormality. International Journal of Research and Reports in Hematology. 2022;5(2): 122-134

Francis RB. Platelets, coagulation, and fibrinolysis in sickle cell disease: their possible role in vascular occlusion. Blood Coagu Fibrinolysis, 2021;2:341–353.

Hankins J and Aygun B. Pharmacoltherary in sicke cell disease: State of the art and future prospects. Br J Haematol, 2019;145(3), 296-308.

Foy H, Kondi A.The variability of sickle cell rates in the tribes of Kenya and Southern sudan. Br Med J, 2014;2(6), 1294-1297.

Tomer A, Harker LA, Kasey S and Eckman JR. Thrombogenesis in sickle cell disease. J Lab Clin Med, 2001;137, 398–407.

Lee SP, Ataga KI, Orringer EP and Parise LV. Biologically active CD40 ligand is elevated in sickle cell disease: potential role for platelet-mediated inflammation. Arterioscler Thromb Vasc, 2006;26, 1626–1631.

Fakunle EE, Eteng KI, Shokunbi WA. D-dimer levels in Patients with Sickle Cell Disease during bone pain crises and in the steady state. Pathol Lab Med Int 2012; 4:1-5.

Hagger D, Wolf S, Owen J, Samson D. Changes in coagulation and fibrinolysis in patients with Sickle Cell Disease compared with healthy black controls. Blood Coagul Fibrinolysis 2015; 6:93-9.

Haut MJ, Cowan DH, Harris JW. Platelets function and survival in sickle cell disease. J Lab Clin Med 2023; 82:44-9.

Francis RB. Elevated fibrin D dimer fragment in sickle cell anaemia: Evidence for activation of coagulation during the steady state as well as in painful crisis. Haemostasis 2019; 19:105-11.

Ataga KI, Orringer EP. Hypercoagulability in sickle cell disease: A curious paradox. Am J Med 2013; 115:721-8.

Akinola NO, Stevens SME, Franklin IM, Nash GB, Stuart J. Subclinical ischaemic episodes during the steady state of sickle cell anaemia. J Clin Pathol 2022; 45:902-6.

Ekwere T, Ogunro SP, Akanmu AS. Assessment of some fibrinolytic proteins in sickle cell anemia patients in steady state and in vaso-occlusive crises. J Appl Hematol 2013; 4:131-6.

Philips G, Hartman J, Keller VA, Santiago MA, Pizzo S. Regulation of tissue plasminogen activator in sickle cell anemia. Am J Hematol 2020; 35:167-70.

Philips G, Mitchell LB, Pizzo SV. Defective release of tissue plasminogen activator in patients with sickle cell anemia. Am J Hematol 2018; 29:52-3.

Nsiri B, Gritli N, Bayoudh F, Messaoud T, Fattoum S, Machghoul S. Abnormalities of coagulation and fbrinolysis in homozygous sickle cell disease. Hematol Cell Ther 2016; 38:279-84.

Francis RB Jr. Tissue type plasminogen activator antigen and activity in sickle cell disease. J Clin Pathol 2018; 41:490-3.

Scarano L, Bernardi E, Prandoni P, Sardella C, Rossi L, Carraro P. Accuracy of two newly described D-dimer tests in patients with suspected deep vein thrombosis. Thromb Res 2017; 86:93-9.

Uche CL, Ezirim EO, Abali IO, Airaodion AI. Implication of Nephropathy in Sickle Cell Anaemia. International Journal of Advances in Nephrology Research. 2022;5(1): 74-81

Stief TW. The laboratory diagnosis of the pre-phase of pathologic disseminated intravascular coagulation. Hemostasis Laboratory. 2008; 1:3–19.

Sparkenbaugh E, Pawlinski R. (2013). Prothrombotic aspects of sickle cell disease. Journal of Thrombosis and Haemostasis, 2013;11(5), 844–855.

Ataga KI, Orringer EP, Styles L. Renal abnormalities in sickle cell disease. American Journal of Hematology, 2007;82(5), 339–345.

Ataga, K. I., & Key, N. S. (2017). Hypercoagulability in sickle cell disease: new approaches to an old problem. Hematology, 2017(1), 358-363.

Key, N. S., Slungaard, A., Dandelet, L., Nelson, S. C., Moertel, C., Styles, L. A., & Kuypers, F. A. (2018). Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood, 91(10), 4216-4223.